Ribometrix

@Ribometrix

Ribometrix is a biotechnology company developing small molecule therapeutics that directly target RNA to treat human diseases.

Durham, NC
Vrijeme pridruživanja: veljača 2017.

Tweetovi

Blokirali ste korisnika/cu @Ribometrix

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @Ribometrix

  1. Prikvačeni tweet
    28. kol 2018.

    Principles for targeting RNA with small molecules

    Poništi
  2. 7. stu 2019.

    strives to provide a fun culture and we enjoy participating in events. Most recently we volunteered with . Working together to truly embodies our and .

    Poništi
  3. 30. ruj 2019.

    Exciting day, as we announce our partnership with Vertex Pharmaceuticals to discover and develop novel RNA-targeted small molecule therapeutic candidates for serious diseases. Full PR here: -targeted_small_molecules

    Poništi
  4. 27. ruj 2019.

    Thrilled to announce $7.8 million in new funding from existing investors, the Dementia Discovery Fund and Illumina Ventures, and the appointment of Mike Clayman, M.D., as chairman of the board.

    Poništi
  5. 11. tra 2019.

    Welcome to John Reardon, our new CSO! He joins Don Hertzog, VP Drug Discovery, and Bill Janzen, VP Lead Discovery, who started in 2018. We are grateful to have these industry leaders join us in our endeavors to develop novel, RNA-targeting therapeutics.

    Poništi
  6. 8. velj 2019.

    is in the news! Founders, Katie Warner and Kevin Weeks, as well as Don Hertzog, VP of Drug Discovery and Mike Dial of Hatteras Venture Partners spoke to a group at about their experience.

    Poništi
  7. 16. sij 2019.
    Poništi
  8. 15. sij 2019.
    Poništi
  9. 13. pro 2018.

    had a successful drive in 2018! Thanks to and everyone who works in the . building for contributing and bringing holiday cheer to these kids!

    Poništi
  10. 29. stu 2018.

    The crew showing off their artistic skills in a collaborative painting of the bull city skyline! Not too shabby, if we do say so ourselves...

    Poništi
  11. proslijedio/la je Tweet
    13. stu 2018.

    Congrats to grantee recipient on completing their $30M fundraising efforts! Ribometrix is a spinoff that has received & funding from the & .

    Poništi
  12. proslijedio/la je Tweet
    14. stu 2018.

    Big news from venture , which just finalized its latest funding round -- this time worth $30 million. This venture works to transform lives by unlocking the disease-fighting potential of RNA.

    Poništi
  13. proslijedio/la je Tweet
    13. stu 2018.

    “The nice thing about a platform like this, and going against undruggable targets, is that you can go across all sorts of indications,” said CEO Solomon, who helped found Epizyme and served as its VP of discovery:

    Poništi
  14. proslijedio/la je Tweet
    13. stu 2018.

    Merck, Amgen back a $30M play for Ribometrix — one of the upstarts making its mark in drugging RNA

    Poništi
  15. 4. lis 2018.

    Congratulations to the RBX team for winning the Biolabs Pipetting Olympics !!!

    Poništi
  16. proslijedio/la je Tweet
    4. lis 2018.

    with a like performance in the Pipette Olympics. Overall winner and winner of 3/4 individual events! Thanks to all the teams that participated and thanks to for organizing the event.

    Poništi
  17. 3. lis 2018.

    Join our growing team of smiling faces. We are hiring for several positions! Research Associate: Associate Director, Molecular Biology:

    Poništi
  18. 20. ruj 2018.
    Poništi
  19. 18. ruj 2018.

    is proud to sponsor the Carolina Biophysics Symposium, October 25-26 in . Sessions will focus on RNA Structure and Dynamics, Cellular Microenvironments, Protein Engineering & Design, & Blood Coagulation.

    Poništi
  20. 12. ruj 2018.

    Around lab at Ribometrix: science in action!

    Poništi
  21. 30. kol 2018.
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·